[Complex assessment of inhacort effectiveness in bronchial asthma].
OBJECTIVE
To investigate efficiency of inhacort in long-term (6 months to 2 years) treatment of bronchial asthma (BA).


METHODS
67 inpatients and 65 outpatients with moderate BA were divided into two groups. 96 patients of group 1 had received standard combined treatment without glucocorticosteroids (GCS), 36 patients of group 2 had received GCS. Inpatients were given inhacort in a dose 1000 micrograms/day, outpatients took inhacort in a daily dose 500 micrograms/day. The examination scheme included assessment of external respiration function (ERF), blood hydrocortisone, sputum rheology and diagnosis of candidosis.


RESULTS
Inhacort treatment has reduced frequency of asphyxia attacks 2.5-fold 30 and 25% of the patients stopped taking sympathomimetics and GCS, respectively. None of the patients had asphyxia as a status. ERF, sputum viscosity improved, hydrocortisone secretion was unchanged. Only 3.8% of the patients developed oral candidosis.


CONCLUSIONS
Inhacort in a dose 1 mg controls BA. 73% of the patients treated outpatiently had no need in hospitalization.
Kakhnovskiĭ
I M
IM
Marinin
V F
VF
Arkhipova
S V
SV
Sorokina
L A
LA
Makhnach
G K
GK
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D005446:Fluocinolone Acetonide; C007734:flunisolide; D006854:Hydrocortisone
Kompleksnaia otsenka éffektivnosti ingakorta pri lechenii bol'nykh bronkhial'noĭ astmoĭ.